Destiny Pharma PLC (AIM:DEST) hailed the progress made with its two lead assets.
In an update alongside interim results, it said a phase III evaluation of the NTCD-M3 programme targeting C. difficile (CDI (NYSE:CDI)) is on track to begin in the second half of next year.
“As we finalise the phase III study design and network with CDI (NYSE:CDI) medical experts, we are increasingly enthused by the positioning of NTCD-M3 as a single strain, natural biotherapeutic and its great potential in a large market where peak global product sales could reach US$1bn,” the clinical stage, innovative biotechnology company told investors.
Discussions are progressing around the study design for its XF-73 nasal gel for the prevention of post-surgical infections, the company added.
“We are very pleased with the quality of the XF-73 nasal phase IIb data and are now focused on clarifying the phase III trial designs in the US and Europe,” Destiny said.
“We are confident that XF-73 has the potential to deliver a major improvement in the prevention of post-surgical infections caused by Staphylococcus aureus.”
The innovation meets a “clear clinical need” and therefore has blockbuster potential. It believes peak annual sales could be US$1bn in the US alone, the statement said.
Cash resources stood at £7.1mln, enough to fund it to the final quarter of next year.
It posted a loss of almost £3mln due to investment in R&D.